Advair Diskus is a combination inhaled corticosteroid and long-acting beta2-adrenergic agonist (ICS/LABA) designed for the maintenance treatment of asthma and chronic obstructive pulmonary disease (COPD). It delivers two active ingredients—fluticasone propionate and salmeterol—in a single, easy-to-use inhalation device. This medication is indicated for patients who require both anti-inflammatory and bronchodilator therapies to achieve optimal respiratory control. It is not intended for immediate relief of acute bronchospasm. Proper technique and adherence to prescribed dosing are critical for therapeutic efficacy and minimizing risks.

Features

• Contains fluticasone propionate (corticosteroid) and salmeterol (long-acting bronchodilator)
• Available in multiple strength combinations: 100/50, 250/50, and 500/50 mcg
• Delivered via a breath-actuated Diskus inhalation device
• Pre-measured, dry powder formulation for consistent dosing
• Does not require shaking or coordination with actuator release
• Each blister contains a single dose; device includes a dose counter

Benefits

• Reduces airway inflammation and prevents bronchoconstriction
• Decreases frequency and severity of asthma exacerbations
• Improves lung function (FEV1) and overall symptom control
• Enhances quality of life through sustained respiratory management
• Convenient twice-daily dosing supports adherence
• May reduce reliance on short-acting rescue inhalers

Common use

Advair Diskus is prescribed for the maintenance treatment of asthma in patients aged 4 years and older, as well as for airflow obstruction and reducing exacerbations in patients with COPD, including chronic bronchitis and/or emphysema. It is used when a patient’s condition is not adequately controlled with inhaled corticosteroids alone or when disease severity warrants dual therapy from the outset.

Dosage and direction

For asthma: The recommended dosage is based on disease severity and prior treatment. Typical starting doses for adults and children aged 12 and older are 100/50 mcg or 250/50 mcg twice daily (approximately 12 hours apart). For children aged 4–11, the recommended dose is 100/50 mcg twice daily.
For COPD: The recommended dose is 250/50 mcg twice daily.
Instruct patients to inhale deeply and forcefully through the mouthpiece. Do not exhale into the device. Rinse mouth with water after each dose to reduce the risk of oropharyngeal candidiasis. Do not swallow the water.

Precautions

• Not for relief of acute symptoms; ensure patients have a short-acting beta2-agonist available
• Increased risk of pneumonia in patients with COPD; monitor for signs and symptoms
• May cause systemic corticosteroid effects with high doses or prolonged use (e.g., adrenal suppression, reduced bone mineral density)
• Potential for paradoxical bronchospasm; discontinue immediately if it occurs
• Use with caution in patients with cardiovascular disorders, seizures, or thyrotoxicosis
• May mask signs of infection; monitor patients with active or quiescent tuberculosis, fungal, bacterial, or viral infections

Contraindications

• Primary treatment of status asthmaticus or other acute episodes of asthma or COPD
• Hypersensitivity to fluticasone propionate, salmeterol, or milk proteins (the delivery formulation contains lactose)
• Significant, untreated fungal, bacterial, or tuberculosis infections of the respiratory tract

Possible side effects

Common side effects may include:

• Headache
• Throat irritation
• Hoarseness or dysphonia
• Oropharyngeal candidiasis
• Upper respiratory tract infection
• Cough
  Serious side effects (seek medical attention if they occur):
• Pneumonia (especially in COPD patients)
• Increased blood pressure or heart rate
• Chest pain or palpitations
• Adrenal insufficiency
• Severe allergic reactions (rash, hives, swelling, bronchospasm)
• Osteoporosis or reduced growth velocity in children

Drug interaction

• Avoid concomitant use with strong CYP3A4 inhibitors (e.g., ketoconazole, ritonavir) due to increased systemic exposure to salmeterol and risk of cardiovascular effects
• Use caution with other beta-adrenergic drugs (may potentiate sympathetic effects)
• Diuretics or steroids may exacerbate hypokalemia or hyperglycemia
• Monoamine oxidase inhibitors and tricyclic antidepressants may potentiate the effect of salmeterol on the vascular system

Missed dose

If a dose is missed, it should be taken as soon as remembered, unless it is almost time for the next dose. Do not double the dose to make up for a missed one. Resume the regular dosing schedule.

Overdose

Overdosage may lead to exaggerated pharmacologic effects such as tachycardia, arrhythmias, tremor, headache, and hyperglycemia. Cardiac arrest and even death may occur. Symptomatic supportive therapy is indicated. There is no specific antidote. Cardiac monitoring is recommended in cases of significant overdose.

Storage

Store at room temperature (20–25°C or 68–77°F) in a dry place. Keep in the foil pouch until ready to use. Do not store in moist or humid conditions (e.g., bathroom). Discard 1 month after removal from foil or when the dose counter reads “0,” whichever comes first. Keep out of reach of children and pets.

Disclaimer

This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or medication. Do not disregard professional medical advice or delay in seeking it because of something you have read here.

Reviews

Clinical studies and patient reports consistently demonstrate improved symptom control and reduced exacerbation frequency with regular use of Advair Diskus. Many users note significant improvement in daily functioning and quality of life. However, individual responses may vary, and adherence to prescribed dosing and technique is crucial for optimal outcomes. Always discuss your experience and any side effects with your healthcare provider.